New substituted 4-arylaminoquinazolines as potent inhibitors of breast tumor cell lines: in vitro and docking experiments.
The arylquinazolines represent significant advances in the clinical management of breast cancer. Nevertheless some confirmatory studies must be considered to foster the use of anti-EGFR therapies including safety and clinical use. Two 4-arylaminoquinazoline derivatives, recently synthesized, were tested as kinase inhibitors and their citotoxicities showed potent growth inhibitory activity in breast tumor cell lines (MCF-7). The predicted complex structure of quinazoline inhibitors with EGFR protein from molecular docking provided a stereoview of the binding site correlated with structure activity, affording important information about structure-based drug design.
de Oliveira
André N
AN
Department of Clinical Pathology, School of Medical Sciences, State University of Campinas, POB 6111, 13083-887 Campinas, SP, Brazil.
Bocca
Cleverson C
CC
Carvalho
João E
JE
Ruiz
Ana Lúcia G
AL
Silva
Thiago P
TP
Rittner
Roberto
R
Hoehr
Nelci F
NF
D001943:Breast Neoplasms / Q000473:pathology*; D045744:Cell Line, Tumor; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D008958:Models, Molecular; D011487:Protein Conformation; D011799:Quinazolines / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology*
D011799:Quinazolines; D066246:ErbB Receptors